Purigen Biosystems Raises $26.4 Million Series B Financing to Accelerate Commercialization of Automated Sample Preparation Platform Latest funding led by Agilent Technologies with participation from Cota Capital, 5AM Ventures, and Roche Venture Fund PLEASANTON, Calif., June 12, 2019-- Purigen Biosystems, Inc., a leading provider of next-generation technologies for extracting, enriching, and quantifying nucleic acids from biological samples, today announced the completion of a $26.4 million Series B financing. The latest round of funding was led by Agilent Technologies and included participation from new investor Cota Capital, along with existing investors 5AM Ventures and Roche Venture Fund.